ACR Meeting Abstracts

ACR Meeting Abstracts

Abstract Number: 1469

Manhattan Study: Observational, Ambispective Study to Describe Persistence and Effectiveness of a Second-line Guselkumab or TNF Inhibitors After First-line TNF Inhibitors for the Treatment of Active Psoriatic Arthritis in Spain

María Rocío González Molina1, C Marín Huertas2, B Joven-Ibáñez3, L de Prado4, Lourdes Mateo5, M Llanes Gómez6, A Hernández del Río7, EA Blanco-Morales8, J Malavé Calzada9, Meritxell Sallés Lizarzaburu10, Inmaculada Ros-Vilamajó11, Martina Steiner12, EVELIN CERVANTES PEREZ13, Vanesa Hernández-Hernández14, S Castro Oreiro15, ANA URRUTICOECHEA16, L Orpinell Palacio17, J Campos Esteban18, Raúl Veroz González19, O Camacho Alcázar20, MP Moreno-Gil21, A Aragón Díez22, MJ Moreno-Ramos23, FJ Maceiras Pan24, S Díaz-Castroverde25, Santiago Muñoz Fernández26, JA Pinto Tasende27 and J Ramírez García28, 1Hospital Reina Sofía, Murcia, Murcia, Spain, 2Hospital Infanta Leonor, Madrid, Madrid, Spain, 3Hospital Universitario 12 de Octubre, Madrid, Madrid, Spain, 4Hospital de Mollet, Mollet del Vallès, Barcelona, Catalonia, Spain, 5H Germans Trias i Pujol, Barcelona, Spain, 6Hospital Juan Ramón Jiménez, Huelva, Andalucia, Spain, 7Hospital Naval, Ferrol, A Coruña, Galicia, Spain, 8Hospital Virgen del Rocío, Sevilla, Andalucia, Spain, 9Hospital Virgen del Puerto, Plasencia, Cáceres, Extremadura, Spain, 10Althaia Xarxa Assistencial Universitària Manresa, Manresa, Catalonia, Spain, 11Hospital Universitari Son Llàtzer, Palma de Mallorca, Islas Baleares, Spain, 12Department of Rheumatology. Hospital Universitario Infanta Sofía., Madrid, Spain, 13Complejo Hospitalario Universitario de Pontevedra, Pontevedra, Galicia, Spain, 14Hospital Universitario de Canarias, San Cristobal de La Laguna, Canarias, Spain, 15Hospital Sant Joan XXIII, Tarragona, Catalonia, Spain, 16Hospital Universitario Son Espases, Palma de Mallorca, Islas Baleares, Spain, 17Hospital Sagrat Cor, Barcelona, Spain, 18Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain, 19Hospital Mérida, Badajoz, Spain, 20Hospital Sant Joan Despí Moisès Broggi, Sant Joan Despí, Barcelona, Catalonia, Spain, 21Hospital San Pedro de Alcántara, Cáceres, Extremadura, Spain, 22Hospital Universitario de Getafe, Getafe, Madrid, Madrid, Spain, 23Hospital Virgen de Arrixaca, Murcia, Murcia, Spain, 24Hospital de Meixoeiro, Pontevedra, Galicia, Spain, 25Johnson&Johnson Innovative Medicine, Madrid, Madrid, Spain, 26Hospital Universitario Infanta Sofía. Universidad Europea de Madrid, Madrid, Spain, 27Complejo Hospitalario Universitario, A Coruña, Spain, 28Hospital Clínic, Barcelona, Spain

Meeting: ACR Convergence 2024

Keywords: ,

Session Information

Date: Sunday, November 17, 2024

Title: SpA Including PsA – Treatment Poster II

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: PsA is a complex inflammatory condition affecting both the skin and musculoskeletal system. Clinical guidelines recommend biological therapies after conventional synthetic DMARDs (csDMARDs) inadequate response or intolerance. However, limited information has been published about biological therapies sequencing in clinical practice in terms of effectiveness and survival. Manhattan study aims to describe the effectiveness of guselkumab (GUS) or a second-line TNF inhibitor (TNFi) after receiving a first-line TNFi.

Methods: Manhattan (CNTO1959PSA4009) is an ongoing ambispective, observational cohort, study of patients with PsA in 34 hospitals in Spain. The study is evaluating effectiveness, persistence and tolerability of second-line GUS or TNFi patients after receiving a first-line TNFi treatment. An interim analysis was performed 10 months after the inclusion of the first patient. Sixty-nine participants (GUS n=36, TNFi n=33) had data available at week 12 and 56.5% (GUS n=25, TNFi n=14) at week 24, the maximum follow-up period in this analysis.

Results: Baseline clinical and demographic characteristics were described among all included patients for GUS and TNFi group, respectively. The mean age at PsA diagnosis was 42.8 for both groups, similar mean BMI was described (27.6 kg/m2 GUS and 29.3 kg/m2 TNFi) with 55.6% and 45.5% of females in GUS and TNFi group, respectively. The predominance of PsA characteristics were described for GUS and TNFi respectively: polyarticular PsA (63.9%, 78.1%); oligoarticular PsA (30.6%, 21.2%); mean Tender Joint Count (TJC) (5.7, 4.8); mean Swollen Joint Count (SJC) (3.5, 2.9); enthesitis (25.0%, 34.4%); dactylitis (19.4%, 12.5%); nail psoriasis (38.9%, 36.4%) and active psoriasis (66.7%, 45.5%). Concomitant csDMARDs at second-line were used in 38.9% of GUS patients and 51.5% of TNFi patients.

The percentage of patients with Disease Activity in Psoriatic Arthritis (DAPSA) Low Disease Activity (LDA) (≤ 14) increased over the time in both groups. After 24 weeks, 77.8% GUS patients and 69.2% TNFi patients were in DAPSA LDA (Figure 1). Accordingly, number of TJC and SJC were decreased over the time in both groups (Figure 2). Despite the baseline mean Body Surface Area (BSA) of 5.5% for GUS patients (Figure 3), 86.2% of patients had BSA ≤ 3% at week 12.

After 24 weeks, 95.7% of patients were still treated with GUS (1 patient suspended for patient desire) and 78.3% with TNFi (3 patient suspended due to adverse events and 1 due to primary failure).  

One adverse drug reaction (ADR) was reported for GUS patients (headache) and four for TNFi patients (upper respiratory tract infection, syncope, alopecia, and skin reaction). No severe ADR was reported.

Conclusion: Among patients included in this interim analysis, DAPSA LDA was reached similarly after 24 weeks GUS or TNFi treatment whereas the probability of persistence to treatment was slightly higher in the GUS group.

Supporting image 1

Supporting image 2

Supporting image 3

Disclosures: M. González Molina: None; C. Marín Huertas: None; B. Joven-Ibáñez: AbbVie/Abbott, 2, 6, Amgen, 6, Bristol-Myers Squibb(BMS), 2, 5, Eli Lilly, 5, 6, Janssen, 2, 6, Novartis, 2, 6, UCB, 6; L. de Prado: AstraZeneca, 6, Janssen, 12, collaborating researcher in a clinical trial; L. Mateo: None; M. Llanes Gómez: None; A. Hernández del Río: None; E. Blanco-Morales: None; J. Malavé Calzada: None; M. Sallés Lizarzaburu: None; I. Ros-Vilamajó: None; M. Steiner: None; E. CERVANTES PEREZ: None; V. Hernández-Hernández: None; S. Castro Oreiro: None; A. URRUTICOECHEA: AbbVie/Abbott, 6, Amgen, 6, Galápagos, 6, GlaxoSmithKlein(GSK), 1, Janssen, 6, Lilly, 6, Novartis, 1, UCB, 6; L. Orpinell Palacio: None; J. Campos Esteban: Janssen, 6; R. Veroz González: None; O. Camacho Alcázar: None; M. Moreno-Gil: None; A. Aragón Díez: None; M. Moreno-Ramos: None; F. Maceiras Pan: None; S. Díaz-Castroverde: Janssen, 3; S. Muñoz Fernández: AbbVie/Abbott, 1, 6, AstraZeneca, 5, GlaxoSmithKlein(GSK), 5, Janssen, 1, 2, 6, Novartis, 5, UCB, 6; J. Pinto Tasende: AbbVie/Abbott, 1, 6, Amgen, 1, 6, Bristol-Myers Squibb(BMS), 6, Eli Lilly, 6, Janssen, 1, 6, Novartis, 1, 6; J. Ramírez García: None.

To cite this abstract in AMA style:

González Molina M, Marín Huertas C, Joven-Ibáñez B, de Prado L, Mateo L, Llanes Gómez M, Hernández del Río A, Blanco-Morales E, Malavé Calzada J, Sallés Lizarzaburu M, Ros-Vilamajó I, Steiner M, CERVANTES PEREZ E, Hernández-Hernández V, Castro Oreiro S, URRUTICOECHEA A, Orpinell Palacio L, Campos Esteban J, Veroz González R, Camacho Alcázar O, Moreno-Gil M, Aragón Díez A, Moreno-Ramos M, Maceiras Pan F, Díaz-Castroverde S, Muñoz Fernández S, Pinto Tasende J, Ramírez García J. Manhattan Study: Observational, Ambispective Study to Describe Persistence and Effectiveness of a Second-line Guselkumab or TNF Inhibitors After First-line TNF Inhibitors for the Treatment of Active Psoriatic Arthritis in Spain [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/manhattan-study-observational-ambispective-study-to-describe-persistence-and-effectiveness-of-a-second-line-guselkumab-or-tnf-inhibitors-after-first-line-tnf-inhibitors-for-the-treatment-of-active-p/. Accessed .

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/manhattan-study-observational-ambispective-study-to-describe-persistence-and-effectiveness-of-a-second-line-guselkumab-or-tnf-inhibitors-after-first-line-tnf-inhibitors-for-the-treatment-of-active-p/